-
公开(公告)号：US20190091377A1
公开(公告)日：2019-03-28
申请号：US16206937
申请日：2018-11-30
Applicant: Massachusetts Institute of Technology
Inventor： Christopher J. Bettinger , Joost P. Bruggeman , Lino da Silva Ferreira , Jeffrey M. Karp , Robert S. Langer , Christiaan Nijst , Andreas Zumbuehl , Jason Burdick , Sonia J. Kim
IPC: A61L31/06 , A61L31/14 , A61L27/18 , A61K45/06 , A61K35/48 , A61K35/12 , A61L27/38 , A61L27/58 , C08G63/685 , C12N11/08 , C08K5/00 , C08J3/24 , C08L67/00 , C08L67/07
Abstract: The present inventions in various aspects provide elastic biodegradable polymers. In various embodiments, the polymers are formed by the reaction of a multifunctional alcohol or ether and a difunctional or higher order acid to form a pre-polymer, which is cross-linked to form the elastic biodegradable polymer. In preferred embodiments, the cross-linking is performed by functionalization of one or more OR groups on the pre-polymer backbone with vinyl, followed by photopolymerization to form the elastic biodegradable polymer composition or material. Preferably, acrylate is used to add one or more vinyls to the backbone of the pre-polymer to form an acrylated pre-polymer. In various embodiments, acrylated pre-polymers are co-polymerized with one or more acrylated co-polymers.
-
公开(公告)号：US20190091139A1
公开(公告)日：2019-03-28
申请号：US16200334
申请日：2018-11-26
Inventor： Minglin Ma , Daniel G. Anderson , Robert S. Langer , Omid Veiseh , Joshua Charles Doloff , Delai Chen , Christian J. Kastrup , Arturo Jose Vegas
Abstract: Biomedical devices for implantation with decreased pericapsular fibrotic overgrowth are disclosed. The device includes biocompatible materials and has specific characteristics that allow the device to elicit less of a fibrotic reaction after implantation than the same device lacking one or more of these characteristic that are present on the device. Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.
-
公开(公告)号：US20190046690A9
公开(公告)日：2019-02-14
申请号：US15341118
申请日：2016-11-02
Inventor： Arturo J. Vegas , Joshua C. Doloff , Omid Veiseh , Robert S. Langer , Daniel G. Anderson
Abstract: Products, such as devices, prostheses, and materials, whose surfaces have been modified in order to impart beneficial properties to these products are disclosed. The surface-modified products have improved biocompatibility compared to a corresponding product that lacks the modification. Following implantation in a subject, the surface-modified products induce a lower foreign-body response, compared to a corresponding unmodified product.
-
公开(公告)号：US10201655B2
公开(公告)日：2019-02-12
申请号：US14421267
申请日：2013-08-07
Inventor： Eoin D. O'Cearbhaill , Bryan Laulicht , Alexander H. Slocum , Robert S. Langer , Omid C. Farokhzad , Jeffrey M. Karp
Abstract: An apparatus provides targeted placement of openings for infusing fluids into a body. The apparatus provides a driving force to a penetrating medical device, such as a needle, when the apparatus tip encounters material of high resistance. When the apparatus tip encounters a low resistance material, no further driving force is applied to the apparatus due to contraction of an element made of interlaced flexible elements. A multi-opening needle is provided in some embodiments wherein placement of one of the openings in a target region with a relatively lower external pressure allows pressurized fluid to exit the needle while openings remaining in higher pressure, non-target regions do not release substantial amounts of the fluid.
-
公开(公告)号：US20180353650A1
公开(公告)日：2018-12-13
申请号：US16007922
申请日：2018-06-13
Inventor： Suman Bose , Volkan Yesilyurt , Lisa Rae Volpatti , Robert S. Langer , Daniel G. Anderson
CPC classification number: A61L27/3834 , A61K9/0024 , A61L27/16 , A61L27/34 , A61L27/38 , A61L27/52 , A61L29/041 , A61L31/048 , C08F20/18 , C08F2438/01 , C08L33/26 , C08L2203/02
Abstract: Macrodevices containing a micro-fabricated body having at least one or multiple compartments and a porous membrane, methods of making and using thereof, are described. The one or multiple compartments encapsulate one or more cells that secrete a therapeutic agent in cell-based therapy. The porous membrane provides immunoprotection the encapsulated cells. Further, the surface of the macrodevices is chemically modified using polymers and/or small molecules, reducing fibrosis of the macrodevices, thereby allowing in vivo delivery of the secreted therapeutic agents for extended periods of time.
-
Patent Agency Ranking
公开(公告)号：US20180353643A1
公开(公告)日：2018-12-13
申请号：US15573926
申请日：2016-05-17
Inventor： Minglin Ma , Daniel G. Anderson , Robert S. Langer , Omid Veiseh , Arturo Jose Vegas , Joshua Charles Doloff , Delai Chen , Christian J. Kastrup
CPC classification number: A61L27/20 , A61F2/02 , A61F2230/0071 , A61F2240/001 , A61F2250/0068 , A61L27/3804 , A61L27/52 , A61L27/54 , A61L2300/64 , A61L2400/18 , A61M31/002 , A61M2205/04 , A61M2207/00
Abstract: Biomedical devices for implantation with decreased pericapsular fibrotic overgrowth are disclosed. The device includes biocompatible materials and has specific characteristics that allow the device to elicit less of a fibrotic reaction after implantation than the same device lacking one or more of these characteristic that are present on the device. Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.
-
公开(公告)号：US09994615B2
公开(公告)日：2018-06-12
申请号：US14379477
申请日：2013-02-19
Inventor： Robert S. Langer , Daniel G. Anderson , Zhen Gu , Alex Arthur Aimetti
Abstract: A glucose binding amphiphilic peptide hydrogel insulin delivery system that is responsive to glucose concentrations under physiological conditions is provided. Insulin is encapsulated in a glucose binding hydrogel, made from self-assembling amphiphilic peptides including a hydrophobic domain including a beta sheet forming region coupled to a charged hydrophilic domain modified to contain a glucose binding segment. The formulations are designed to release insulin as a function of blood glucose level, maintaining the patients' blood glucose level in an optimum range and avoiding both hyper- and hypoglycemia.
-
公开(公告)号：US09931477B2
公开(公告)日：2018-04-03
申请号：US14519114
申请日：2014-10-20
Inventor： Erik Bassett , Jeffrey M. Karp , Robert S. Langer , Omid C. Farokhzad , Alexander H. Slocum
CPC classification number: A61M5/3287 , A61B17/3401 , A61B2090/064
Abstract: An apparatus provides feedback regarding the material in which tip of the apparatus is located as the tip is advanced into matter of varying resistances. The apparatus responds to a change in pressure, force, or other parameter such that when the tip reaches matter of a certain resistance, a change in the parameter is sensed. The apparatus provides a driving force to a penetrating medical device, such as a needle, when the apparatus tip encounters material of high resistance. When the apparatus tip encounters a low resistance material, no further driving force is applied to the apparatus. An inner core may be advanced into the low resistance material for deployment of a gas or a liquid as desired.
-
公开(公告)号：US09931410B2
公开(公告)日：2018-04-03
申请号：US14434300
申请日：2013-10-09
Inventor： Pedro M. Valencia , Eric M. Pridgen , Suresh Gadde , Rohit Karnik , Robert S. Langer , Stephen J. Lippard , Omid C. Farokhzad
IPC: A61K47/48 , A61K45/06 , A61K31/555 , A61K33/24 , A61K9/14 , A61K9/51 , A61K31/4745 , A61K47/34 , A61K47/59 , A61K47/68 , A61K47/69 , B82Y5/00
CPC classification number: A61K47/6937 , A61K9/14 , A61K9/51 , A61K9/5146 , A61K9/5153 , A61K31/4745 , A61K31/555 , A61K33/24 , A61K45/06 , A61K47/34 , A61K47/593 , A61K47/6869 , B82Y5/00 , A61K2300/00
Abstract: Provided herein are compositions that contain a nanoparticle containing a plurality of polymers, wherein at least a fraction of the polymers comprise a hydrophobic polymer, a topoisomerase inhibitor, and a Pt-containing chemotherapeutic agent, where the polymers self-assemble in an aqueous liquid to form the nanoparticle, and where the Pt-containing chemotherapeutic agent and the topoisomerase inhibitor are present within the hydrophobic core of the nanoparticle in a ratio of between about 24:1 to about 1:24. Also provided are methods of reducing the proliferation of a cancer cell and methods of treating cancer in a subject that include the use of these compositions. Also provided are methods of making these nanoparticles.
-
公开(公告)号：US09872911B2
公开(公告)日：2018-01-23
申请号：US14364028
申请日：2012-12-15
Applicant: Massachusetts Institute of Technology
Inventor： Arturo Jose Vegas , Kathryn Ann Whitehead , Daniel Griffith Anderson , Robert S. Langer , Joseph R. Dorkin
IPC: A61K47/34 , A61K9/127 , A61K31/713 , A61K9/51 , C08G73/00 , C08L79/00 , A61K33/00 , A61K38/16 , A61K39/00 , C08G12/06 , C08G12/34 , C12N15/113
CPC classification number: A61K47/34 , A61K9/1271 , A61K9/5146 , A61K31/713 , A61K33/00 , A61K38/16 , A61K39/00 , C08G12/06 , C08G12/34 , C08G73/00 , C08L79/00 , C12N15/113
Abstract: α-Aminoamidine polymers and methods of preparing a-aminoamidine polymers by reacting by reacting one or more amines with one or more isocyanides and one or more aldehydes are described. Methods of preparing a-aminoamidine polymers from commercially available starting materials are also provided, wherein the starting materials are racemic or stereochemically pure. a-Aminoamidine polymers or salt forms thereof are preferably biodegradable and biocompatible and may be used in a variety of drug delivery systems and for other purposes as well such as, for example, coatings, additives, excipients, plastics, and materials, etc. Given the amino moiety of these α-aminoamidine polymers, they are particularly suited for the delivery of polynucleotides. Complexes, micelles, liposomes or particles containing the inventive α-aminoamidine polymers and polynucleotides can be prepared. The inventive α-aminoamidine polymers may also be used in preparing microparticles for drug delivery. They are particularly useful in delivering labile agents given their ability to buffer the pH of their surroundings.
-
-
-
-
-
-
-
-
-
Search Results
376
records
(took 0.046 seconds)
